Date Published: 6 December 2010
Zoledronic acid found to have dual benefits for treatment of multiple myeloma
Work led by the University of Leeds has shown that zoledronic acid, a drug used to protect bone, has anticancer properties too.
Professor J Anthony Child and Professor Walter M Gregory (Clinical Trials Research Unit (CTRU), University of Leeds), Professor Gareth J Morgan (formerly at the University of Leeds), together with colleagues from universities and NHS Trusts across the UK, compared two different types of bisphosphonate drug in patients with multiple myeloma.
They found that zoledronic acid improved survival in these patients when compared against the UK and European standard treatment of clodronic acid (sodium clodronate). This improvement was independent of the drug's ability to prevent skeletal-related injures, showing that zoledronic acid has treatment benefits beyond bone health.
These findings from the Medical Research Council (MRC) Myeloma IX study are published online and in an upcoming Lancet, and are being presented at the American Society of Hematology meeting in Orlando, Florida.
Patients with advanced cancer are given bisphosphonates as part of their standard care to help prevent their bones from becoming weakened. In multiple myeloma, malignant plasma cells in the bone marrow can induce bone destruction, putting patients at high risk of fractures.
Previous work has suggested that some bisphosphonates, including zoledronic acid and clodronic acid, may also destroy cancer cells as well as protecting patients' bones. Zoledronic acid, in particular, was singled out in these early trials. However, no consensus has been reached on its use in standard care regimens for symptomatic multiple myeloma patients.
In this study, the authors compared the effects of two biophosphonates - zoledronic acid and clodronic acid - in a randomised trial. The trial involved 1960 multiple myeloma patients at 120 different UK centres, making it the largest and most comprehensive myeloma trial to date.
The researchers found that zoledronic acid reduced mortality by 16% versus clodronic acid, and extended median overall survival by 5.5 months (50 months versus 44.5 months). Both bisphosphonates were generally well tolerated by the patients.
" The improvement in overall survival with zoledronic acid, which remained significant after adjustment for the reduction in risk of skeletal-related events, adds to the growing clinical evidence supporting anticancer benefits with zoledronic acid in patients with newly diagnosed cancers," according to the authors of the study.
"Although we have not definitively identified the underlying mechanism of action, the early improvement in overall survival with zoledronic acid compared with clodronic acid supports early use of zoledronic acid in multiple myeloma," they concluded.
Source: Leeds University, England (UK).